NAUT — Nautilus Biotechnolgy, Inc.

Nautilus Biotechnology Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Operating Expenses: $16.1 million, a decrease of 14% year-over-year.
• Research and Development Expenses: $9.7 million, down 16% from the previous year, attributed to reduced salaries and development costs.
• General and Administrative Expenses: $6.4 million, a 12% decrease, primarily due to lower stock-based compensation and salaries.
• Cash Position: $143.4 million in cash, cash equivalents, and investments at the end of Q1 2026.
• Cash Burn: $12.8 million for the quarter, benefiting from lower overall spending and $1.1 million from stock option exercises.
• Revenue Guidance: Expected to be approximately $0.5 million for the year, with delays in revenue recognition from the Michael J. Fox Foundation grant.

2. Strategic Updates and Business Highlights

• Commercialization Efforts: Nautilus is focused on building its commercial team, having hired Amber Faust as VP of Global Sales and two additional sales members.
• Early Access Program (EAP): Successful launch with growing interest in the Tau assay and custom assay development; Baylor College of Medicine is the first named EAP customer.
• Technical Progress: Advancements in the Voyager platform and Iterative Mapping assay portfolio, including successful verification and validation of the service lab for processing customer samples.
• Oncology Focus: Progress in narrowing down oncology proteoform targets, with plans to introduce an oncology-focused proteoform assay in the second half of 2026.

3. Forward Guidance and Outlook

• Commercial Launch Timeline: Expected to begin preorders in late 2026, with customer installations starting in early 2027 and general availability of broadscale capabilities in the first half of 2027.
• Cash Runway: Current financial plan supports operations through 2027, allowing for continued investment in strategic initiatives.

4. Bad News, Challenges, or Points of Concern

• Revenue Delays: Revenue recognition associated with the Michael J. Fox Foundation grant has been slower than anticipated due to external factors, impacting short-term revenue expectations.
• Market Entry Risks: The company is still in the early stages of building its commercial sales organization, which may affect customer engagement and sales cycles.
• Geopolitical Risks: Ongoing conflict in the Middle East has caused delays in custom reagent development for the alpha-synuclein proteoform program.

5. Notable Q&A Insights

• Customer Engagement: Currently, Baylor College of Medicine is the only announced EAP customer, but there is significant interest from other academic and nonprofit institutions.
• Pharma Diligence Process: Pharma companies are primarily interested in the unique data generated by Nautilus's technology rather than direct comparisons with existing solutions.
• Technical Hurdles: While progress on the broadscale assay configuration is strong, the company emphasizes the need for rigorous verification and validation before launch readiness.

Overall, Nautilus Biotechnology is making significant strides toward commercialization, with a solid financial position, though it faces challenges related to revenue timing and market entry.